DAFTAR PUSTAKA

1. Booth C, Allard S. Blood transfusion. Transfusion Medicine. 2017; 28(4):

1─7.
2. Astuti WD, Laksono AD. Keamanan darah di Indonesia. 1st ed. Surabaya:
Health Advocacy; 2013.1─5.
3. Luban N. Advances in transfusion medicine : 50 years in hematology.
Hematology. 2008; (2):8─9.
4. Gernsheimer T, Slichter S. Preservation and clinical use of platelets. In
Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et
al. Williams haematology. New York: McGraw-Hill Education; 2016.
2381─91.
5. Nency YM, Sumanti D. Latar belakang penyakit pada penggunaan transfusi
komponen darah pada anak. Sari Pediatri. 2011; 13(3): 159─64.
6. Unit Palang Merah Indonesia Kota Padang. Laporan Tahunan. Kota Padang:,
Unit Palang Merah Indonesia; 2016.7─10.
7. Szczepiorkowski ZM, Dunbar NM. Transfusion guidelines : when to
transfuse. Transfusion Medicine. 2013;(1): 638─45.
8. Zeller M. Chapter 18 : Platelet transfusion,alloimmunization and management
of platelet refractoriness. In Services CB. Clinical Guide to Transfusion.
Canada: Canadian Blood Services; 2016. 1─14.
9. Sahu S, Hemiata , Verma A. Adverse events related to blood transfusion.
Indian Journal of Anaesthesia. 2014; 50(5): 543─53.
10. Rachman A. Trombositopenia refrakter. Jurnal Penyakit Dalam Indonesia.
2015; 2(4): 199.
11. Oren. Alloimmunization from transfusions. Medicine. 2016; (5): 1─7.
12. Kumar H, Gupta P, Mishra D, Sarkar R, Jaiprakash M. Leucodepletion and
blood products. M JAFI. 2006; 62(2): 174─7.
13. Watering VD, Hermans J, Witvliet M, Versteegh M, Brand A. HLA and RBC
immunization after filtered and buffy coat depleted blood transfusion in
 cardiac surgery : a randomized controlled trial. Transfusion. 2003; 43:
765─71.
14. Rebulla P. A mini review on platelet refractoriness. Haematologica. 2005; 90:
247─53.
15. Pavenski K, Freedman J, Semple J. HLA alloimmunization against platelet
transfusions : pathophysiology, significance, prevention and management.
Tissue Antigens. 2012; 79: 237─45.
16. Seftel M, Growe G, Petraszko T. Universal leukoreduction in Canada
decreases platelet alloimmunization and refractoriness. Blood. 2004; 103:
333─9.
17. Bianchi M, Vaglio S, Pupella S, Marano G, Facco G, Liumbruno GM, et al.
Leucoreduction of blood components : an effective way to increase blood
safety ? Blood Transfus. 2016; 14: 214─27.
18. Sharma R, Neelam M. Leukoreduced blood components : advantages and
strategies for its implementation in developing countries. Asian J Transfusions
Sci. 2010; 4(1): 3─8.
19. You J, Jiang X, Zhu A. The study of leukocyte filtration in preventing platelet
transfusion refractoriness. J Clin Transfus Lab Med. 2012; 14(4): 295─7.
20. The Trial to Reduce Alloimmunization to Platelet Study Group. Leukocyte
reduction and ultraviolet B irradiation of platelets to prevent alloimmunization
and refractoriness to platelet transfusions. N Engl J Med. 1997; 557: 1861─8.
21. Gombotz H, Dehkharghany A. Clinical consequences of leukocyte reduction.
European Society of Anaesthesiologists. 2004; (1): 235─40.
22. Djoerban Z. Dasar-dasar transfusi darah. In Buku Ajar Ilmu Penyakit Dalam
Jilid II Edisi IV. Jakarta: Balai Penerbit FKUI; 2007. 682─4.
23. Wang Q, Yang J, Stevens L, Wang D. Research progress of platelet
transfusion in China. Transfus Med Rev. 2016; (1): 1─5.
24. Cardigan R, Williamson L. The quality of platelets after storage for 7 days.
Transfus Med. 2003 March; 13: 173─87.
25. Dumont LJ, Dumont DF, Unger ZM, Siegel A, Szczepiorkowski ZM, Corson
 JS, et al. A randomized controlled trial comparing autologous radiolabeled in
vivo platelet recoveries and survivals of 7 days stored platelet rich plasma and
buffy coat platelets from the same subjects. Transfusion. 2011; 51(6): 1241─8.
26. Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et
al. Williams Hematology. 9th ed. New York: McGraw-Hill Education; 2016.
541─58.
27. Ness P, Braine H, King K. Single-donor platelets reduce the risk of septic
platelet transfusion reactions. Transfusion. 2001; 41: 857─81.
28. Heddle N, Cook R, Blajchman M. Assessing the effectiveness of whole blood-
derived platelets stored as a pool : a randomized block noninferiority trial.
Transfusion. 2005; 45: 896─9.
29. Heddle N, Arnold D, Boye D. Comparing the efficacy and safety of apheresis
and whole blood derived platelet transfusions : A systematic review.
Transfusion. 2008; 48: 1447─52.
30. Haroen H. Darah dan komponen : komposisi, indikasi dan cara pemberian. In
Sudoyo A, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editors. Buku Ajar
Ilmu Penyakit Dalam Jilid II Edisi IV. Jakarta: Pusat Penerbitan Departemen
Ilmu Penyakit Dalam FKUI; 2006. 675─80.
31. Kaufman R, Djulbegovic B, Gernsheimer T. Platelet transfusion : a clinical
practice guideline from the AABB. Ann Intern Med. 2015; 162: 205─8.
32. Zeidler K, Arn K, Senn O. Optimal preprocedural platelet transfusion
threshold for central venous cathether insertions in patients with
thrombocytopenia. Transfusion. 2011; 51: 2269─73.
33. Haas B, Chittams J, Trerotola S. Large-bore tunneled central venous cathether
inssertion in patients with coagulopathy. J Vasc Interv Radiol. 2010; 21: 212.
34. Howard S, Gajjar A, Ribeiro. Safety of lumbar puncture for children with
acute lymphoblastic leukemia and thrombocytopenia. JAMA. 2000; 284:
2222.
35. Vavricka S, Walter R, Irani S. Safety of lumbal puncture for adults with acute
leukemia and restrictive prophylactic platelet transfusion. Ann Hematol. 2003;
 82: 570.
36. Haas F, VanRhenen D, deVries R. National Users’ Board Sanquin Blood
Supply : Blood transfusion guideline. 2011.
37. Holcomb J, Tilley B, Baraniuk S. PROPPR Study Group : Transfusion of
plasma, platelets, and red blood cells in a 1:1:1 vs. a 1:1:2 ratio and mortality
in patientswith severe trauma: The PROPPR Randomized Clinical Trial.
JAMA. 2015; 313: 483─91.
38. Hod E, Schwartz J. Platelet transfusion refractoriness. British Journal of
Haematology. 2008; 142: 348─60.
39. Shastry S, Chaudhary R. Clinical factors influencing corrected count
increment. Transfusion and Apheresis Science. 2012; 47: 327─30.
40. Holbro A, Infanti L, Sigle J, Buser A. Platelet transfusion : basic aspects. The
European Journal of Medical Sciences : Swiss Medical Weekly. 2013; 143:
1─10.
41. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al.
Factors affecting posttransfusion platelet increments, platelet refractoriness
and platelet transfusion intervals in thrombocytopenic patients. Transfusion
Medicine. 2003; 105: 4106─14.
42. Kerkhoffs JLH. Efficacy of platelet transfusions. 1st ed. Leiden : Haga
Teaching Hospital; 2012. 54─84
43. Blackall D. Alloimmunization from transfusions. Medscape. 2017.
44. McFarland JG. Platelet immunology and alloimmunization. In Simon TL,
McCullough J, Snyder L, Solheim BG, Strauss G, editors. Rossi's principle of
transfusion medicine. Milwaukee: John Wiley & Sons, Ltd; 2016. 215─27.
45. Inverardi D, Bocchio C, Rossi L. Clinical, immunologic and technical factors
affecting recovery of platelet count after platelet transfusion. Haematologica.
2002; 87: 893─4.
46. Friedman D, Lukas M, Jawad A, Larson P, Ohene-frempong K, Manno C.
Alloimmunization to platelets in heavily transfused patients with sickle cell
disease. Blood. 1996; 88(8): 3216─22.
47. Abbas AK, Lichtman AH, Pillai S. Basic immunology : functions and
disorders of the immune system. 5th ed. Missouri: Elsevier; 2016. 32─7
48. Sweeney J, Heaton A. Clinical benefits of leukodepleted blood products
Germany: Springer-Verlag; 1995. 45─71.
49. Bruil A, Beugeling T, Feijen J, Aken WGV. The mechanisms of leukocyte
removal by filtration. Transfusion Medicine Reviews. 1995; IX(2): 145─66.
50. Oksanen K. Leukocyte-depleted blood components prevent platelet
refractoriness in patients with acute myeloid leukemia. European Journal of
Haematology. 1994; 53(2): 100─7.
51. Blumberg N, Heal JM. Optimizing platelet transfusion therapy. Blood
reviews. 2004; 18(3): 149─65.
52. Myllyla G, Saarinen U, Koskimies S. Systematic use of leukocytes-free blood
components to prevent alloimmunization and platelet refractoriness in
multitransfused patients with cancer. Vox Sanguinnis. 1993; 65: 286─92.
53. Hao B, Wang Y, Zhou J, Shao S, Dong X. Comparison between the clinical
efficacy of platelet concentrates, derived from buffy coat and apheresis in
tumor patients. Oncology Letters. 2017; 14: 1445─8.
54. Lubis M, Sudoyo AW, Effendy S, Djumhana T, Kuntjoro. Hubungan antibodi
anti trombosit terhadap respon transfusi trombosit pada pasien hemato-
onkologi yang mendapatkan multitransfusi trombosit di RS Dr. Cipto
Mangunkusumo. Jurnal Penyakit Dalam Indonesia. 2015; 2(4): 200─8.
55. Jaime-perez JC, Vazquez-Hernandez KE, Jimenez-Castillo A, Fernandez LT,
Salazar-Riojas R, Gomez-Almaguer D. Platelet survival in hematology
patients assessed by the corrected count increment and other formulas. Am J
Clin Pathol. 2018; 150: 267─72.
56. Triulzi DJ, Assmann SF, Strauss RG, Hess JR, Kaufman RM, Granger S, et al.
The impact of platelet transfusion characteristics on post transfusion platelet
increments and clinical bleeding in patients with hypoproliferative
thrombocytopenia. Blood. 2012; 119(23): 5553─62.
57. Novotny VMJ. Prevention and management of platelet transfusion
 refractoriness. Vox Sang. 1999; 76(1): 1─13.
58. Kluter H, Dorges L, Maass E, Wagner T, Bartels H, Kirchner H. In-vivo
evaluation of random donor platelet concentrates from pooled buffy coats.
Ann Hematol. 1996; 73: 85─9.
59. Anderson N, Gray S, Copplestone J, Chan D, Hamon M, Prentice A, et al. A
prospective randomized study of three types of platelet concentrates in
patients with haematological malignancy : corrected count increments and
frequency of onhemolytic febrile transfusion reactions. Transfus Med. 1997;
7: 33─9.
60. Jackman RP, Deng X, Bolgiano D, Utter GH, Schechteerly C. Leukoreduction
and ultraviolet treatment reduce both the magnitude and the duration of the
HLA antibody response. Transfusion. 2014; 54(3): 672─80.
61. Williamson LM, Wimperis JZ, Williamson P, Copplestone A, Gooi HC,
Morgenstern GR, et al. Bedside filtration of blood products in the prevention
of HLA alloimmunization. Blood. 1994; 83(10): 3028─35.
62. Fletcher CH, DomBourian MG, Millward PA. Platelet transfusion for patients
with cancer. Cancer Control. 2015; 22(1): 47─51.